Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Lava Therapeutics N.V. (LVTX)

Lava Therapeutics N.V. (LVTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 44,616
  • Shares Outstanding, K 25,350
  • Annual Sales, $ 6,770 K
  • Annual Income, $ -41,970 K
  • 60-Month Beta 0.51
  • Price/Sales 6.42
  • Price/Cash Flow N/A
  • Price/Book 0.51
Trade LVTX with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -0.34
  • Number of Estimates 2
  • High Estimate -0.30
  • Low Estimate -0.39
  • Prior Year -0.34
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.5304 +9.78%
on 09/06/24
1.9700 -14.72%
on 08/23/24
-0.1100 (-6.15%)
since 08/16/24
3-Month
1.5304 +9.78%
on 09/06/24
2.3900 -29.71%
on 07/17/24
-0.2700 (-13.85%)
since 06/18/24
52-Week
1.1310 +48.54%
on 10/30/23
6.4700 -74.03%
on 02/29/24
-0.0400 (-2.33%)
since 09/18/23

Most Recent Stories

More News
Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:OCEA),(NASDAQ:LVTX),(NYSE:MRK),(NYSE:ABBV) EQNX::TICKER_END

OCEA : 0.9800 (-2.97%)
ONCY : 0.9300 (-2.99%)
ONC.TO : 1.28 (-1.54%)
LVTX : 1.6800 (-4.55%)
MRK : 118.64 (+0.30%)
ABBV : 192.94 (-0.26%)
Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments

ONCY : 0.9300 (-2.99%)
ONC.TO : 1.28 (-1.54%)
LVTX : 1.6800 (-4.55%)
MRK : 118.64 (+0.30%)
ABBV : 192.94 (-0.26%)
LAVA Therapeutics (NASDAQ: LVTX) Enters into Global Licensing Agreement with Seagen (NASDAQ: SGEN) to Develop and Commercialize LAVA-1223

LAVA Therapeutics N.V. (NASDAQ: LVTX) is engaged as a clinical-stage oncology company, which is focused on the research and development

LVTX : 1.6800 (-4.55%)
SGEN : 228.74 (-0.07%)
Seagen and LAVA Therapeutics Announce Exclusive Worldwide License Agreement to Advance LAVA-1223, a Preclinical Gamma Delta Bispecific T Cell Engager for EGFR-Expressing Solid Tumors

Seagen Inc. (Nasdaq: SGEN), a world leader and pioneer in antibody-drug conjugate (ADC) therapies, and LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage immuno-oncology company focused on developing...

SGEN : 228.74 (-0.07%)
LVTX : 1.6800 (-4.55%)
LAVA Therapeutics Highlights Encouraging Clinical Updates on Lead Program, LAVA-051, in Chronic Lymphocytic Leukemia and Multiple Myeloma Patients

Clinical update call featuring LAVA-051 investigator Dr. Arnon Kater and Company management summarized initial Phase 1/2a clinical trial data presented at...

LVTX : 1.6800 (-4.55%)
LAVA Therapeutics Announces Two Appointments to its Board of Directors

James Noble and Jay Backstrom, M.D, M.P.H, bring vast global leadership experiences at public biopharmaceutical companies...

LVTX : 1.6800 (-4.55%)
LAVA Therapeutics to Present Initial Phase 1/2a Clinical Trial Dose Escalation Data of LAVA-051 in Chronic Lymphocytic Leukemia and Multiple Myeloma Patients at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

LAVA Therapeutics to host clinical results conference call and webcast on June 16 at 8:00 a.m. EDT/2:00 p.m. ...

LVTX : 1.6800 (-4.55%)
LAVA Therapeutics Announces Annual Meeting of Shareholders

UTRECHT, The Netherlands and PHILADELPHIA, May 31, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX) (LAVA), a clinical stage...

LVTX : 1.6800 (-4.55%)
LAVA Therapeutics Provides Business Update and Reports First Quarter Financial Results

LAVA-051 updated interim clinical data from Phase 1/2a clinical trial in patients with relapsed or refractory chronic lymphocytic leukemia and multiple...

LVTX : 1.6800 (-4.55%)
LAVA Therapeutics to Participate at the UBS Global Healthcare Conference

UTRECHT, The Netherlands and PHILADELPHIA, May 05, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), an immuno-oncology company focused on...

LVTX : 1.6800 (-4.55%)

Business Summary

LAVA Therapeutics B.V. is a biotechnology company. It focuses on applying its expertise in bispecific gamma-delta T cell engagers to transform cancer therapy. LAVA Therapeutics B.V. is based in UTRECHT, The Netherlands.

See More

Key Turning Points

3rd Resistance Point 1.8233
2nd Resistance Point 1.7867
1st Resistance Point 1.7333
Last Price 1.6800
1st Support Level 1.6433
2nd Support Level 1.6067
3rd Support Level 1.5533

See More

52-Week High 6.4700
Fibonacci 61.8% 4.4305
Fibonacci 50% 3.8005
Fibonacci 38.2% 3.1705
Last Price 1.6800
52-Week Low 1.1310

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar